Interaction of the PAS B Domain with HSP90 Accelerates Hypoxia-Inducible Factor-1α StabilizationKatschinski D.M.1 · Le L.2 · Schindler S.G.2 · Thomas T.3 · Voss A.K.3 · Wenger R.H.4
1Cell Physiology Group, Medical Faculty, Martin-Luther-University Halle, Germany, 2Institute of Physiology, University of Lübeck, Germany, 3The Walter and Eliza Hall Institute of Medical Research, Victoria, Australia, 4Institute of Physiology, University of Zürich, Switzerland
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Hypoxia-inducible factor (HIF) α subunits are induced under hypoxic conditions, when limited oxygen supply prevents prolyl hydroxylation-dependent binding of the ubiquitin ligase pVHL and subsequent proteasomal degradation. A short normoxic half-life of HIF-α and a very rapid hypoxic protein stabilization are crucial to the cellular adaptation to changing oxygen supply. However, the molecular requirements for the unusually rapid mechanisms of protein synthesis, folding and nuclear translocation are not well understood. We and others previously found that the chaperone heat-shock protein 90 (HSP90) can interact with HIF-1α in vitro. Here we show that HSP90 also interacts with HIF-2α and HIF-3α, suggesting a general involvement of HSP90 in HIF-α stabilization. The PAS B domain, common to all three α subunits, was required for HSP90 interaction. ARNT competed with HSP90 for binding to the PAS B domain since an excess of either component inhibited the activity of the other. HSP90 as well as the heterocomplex members HSP70 and p23, but not HSP40, were detected in immunoprecipitations of endogenous cellular HIF-1α. While HSP90 and HSP70 bound to HIF-1α predominantly under normoxic conditions, ARNT bound to HIF-1α primarily under hypoxic conditions, suggesting that ARNT displaced HSP90 from HIF-1α following nuclear translocation. Hypoxic accumulation of HIF-1α was delayed in a novel cell model deficient for HSP90β as well as after treatment of wild-type cells with the HSP90 inhibitor geldanamycin, suggesting that HSP90 activity is involved in the rapid HIF-1α protein induction.
© 2004 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.